CTMC has entered into a collaborative partnership with Einstein Hospital Israelita in São Paulo, Brazil, aimed at accelerating the adoption of cell therapy in Brazil and all of Latin America.
"We’re honoured to welcome Einstein Hospital Israelita as the first international member of our alliance,” said Amy Hay, Chief Business Officer of CTMC.
"The CTMC Network Alliance programme creates value through the sharing of proprietary reagents, in-depth training programmes and strategic alignment to increase access to cell therapy globally."
"With CTMC’s experience, we are in a unique position to aggregate leadership in cell therapy to form a global community focused on democratising access to transformative cell therapies."
The Latin American cell therapy market generated more than $46m in revenue in 2023 and is projected to grow at a 15% annual rate, reaching $129m within five years.
This surge is driven by a growing and ageing population, alongside rising awareness amongst patients and healthcare professionals.
Brazil is poised to lead this transformation, already capturing 52.5% of the regional cell therapy market and establishing itself as a hub for precision medicine.
However, access remains a critical challenge — more than 90% of cancer patients in Latin America still lack access to cellular therapies due to insufficient infrastructure and a shortage of trained clinicians and scientists.
Einstein is positioned to close this gap.
The hospital will drive the region’s shift toward personalised, data-driven care — accelerating the adoption of cell therapy and setting a new standard for precision medicine across LATAM.
Einstein is already working in the field of cell therapy, offering treatments such as CAR-T therapy for certain types of hematologic cancers, as well as in ophthalmology and neurology, in addition to conducting various studies in other specialities such as orthopaedics, neurology and rheumatology.
Additionally, the hospital has a cord blood bank and a GMP cell therapy laboratory, which are both essential for the advancement and application of these technologies in the country.
"Einstein has always been at the forefront of medicine, being a pioneer in Latin America in offering therapies such as CAR-T and CAR-NK cells."
"Now, alongside the CTMC Network Alliance, we will take an even greater leap, building a centre of excellence in precision medicine that will benefit not only Brazil, but the entire region," said Sidney Klajner, President of Einstein.
The goal of the Network Alliance is to develop a world-class cell therapy processing and industrialised manufacturing network that sets a new benchmark for quality, accessibility and innovation to be democratised globally.
Members will benefit from CTMC’s comprehensive resources, including education and training programmes, standards and operating procedures and access to proprietary reagents and materials.
The Alliance also serves as a central hub bringing together cell therapy scientific leaders to create collaborations across early discovery, translational science and ultimately, commercial therapeutics.
“Cell therapy democratisation requires collaboration on a global basis. By working with Alliance members, we can accelerate their ability to develop local processing and manufacturing."
"We are proud to have Einstein as our first Alliance member and are eager to share our deep knowledge of the development and manufacture of TIL therapies," said Jason Bock, CEO, CTMC.